RSCM
JUNO

Rock Springs Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Rock Springs Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-230,000
Closed -$10.5M – 164
2017
Q4 		$10.5M Buy
230,000
+5,000
+2% +$249K 0.48% 72
2017
Q3 		$10.1M Hold
225,000
– – 0.47% 71
2017
Q2 		$6.72M Buy
225,000
+27,999
+14% +$691K 0.34% 86
2017
Q1 		$4.37M Hold
197,001
– – 0.25% 94
2016
Q4 		$3.71M Hold
197,001
– – 0.25% 90
2016
Q3 		$5.91M Hold
197,001
– – 0.37% 79
2016
Q2 		$7.57M Hold
197,001
– – 0.56% 54
2016
Q1 		$7.5M Hold
197,001
– – 0.63% 49
2015
Q4 		$8.66M Hold
197,001
– – 0.66% 53
2015
Q3 		$8.02M Buy
197,001
+1
+0% +$44 0.65% 54
2015
Q2 		$10.5M Buy
197,000
+74,574
+61% +$3.96M 0.77% 42
2015
Q1 		$7.43M Sell
122,426
-22,000
-15% -$1.07M 0.69% 51
2014
Q4 		$7.54M Buy
+144,426
New +$6.46M 0.88% 40

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Rock Springs Capital Management's JUNO Position: Q1 2018 in Review

Rock Springs Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 230,000 shares — an estimated $10.5M sold.

Rock Springs Capital Management first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $10.5M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Rock Springs Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Rock Springs Capital Management sold 230,000 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $10.5M.
  • Rock Springs Capital Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Rock Springs Capital Management's Juno Therapeutics, Inc. position peaked at $10.5M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Rock Springs Capital Management's 13F filing for Q1 2018, filed 15 May 2018.